|
Valoración de DCF de Eledon Pharmaceuticals, Inc. (ELDN)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Eledon Pharmaceuticals, Inc. (ELDN) Bundle
¡Mejore sus estrategias de inversión con Eledon Pharmaceuticals, Inc. (ELDN) Calculadora DCF! Explore los datos financieros auténticos, ajuste las proyecciones y gastos de crecimiento, y visualice instantáneamente cómo estos cambios afectan el valor intrínseco de Eledon Pharmaceuticals, Inc. (ELDN).
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | -100 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -15.8 | -23.0 | -36.7 | -87.6 | .0 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | -19193.33 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .2 | .2 | .2 | .4 | 43.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 152.5 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -16.0 | -23.2 | -36.9 | -88.0 | -43.0 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | -19345.83 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 8.8 | 114.2 | 84.8 | 56.4 | 51.1 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 91.67 | 100 | 100 | 100 | 98.33 | 98.33 | 98.33 | 98.33 | 98.33 |
Inventories | .9 | 1.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 1072.5 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .3 | 1.4 | 1.8 | 2.2 | 1.0 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 1138.33 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -17.9 | -22.8 | -34.5 | -87.5 | -43.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -18.5 | -21.9 | -32.5 | -86.7 | -1.2 | -1.0 | .0 | .0 | .0 | .0 |
WACC, % | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 |
PV UFCF | ||||||||||
SUM PV UFCF | -.9 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -4 | |||||||||
Equity Value | 3 | |||||||||
Diluted Shares Outstanding, MM | 25 | |||||||||
Equity Value Per Share | 0.14 |
What You Will Get
- Comprehensive ELDN Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are automatically computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Eledon Pharmaceuticals' future performance.
- User-Friendly Design: Created for industry professionals while remaining accessible to newcomers.
Key Features
- Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Eledon Pharmaceuticals, Inc. (ELDN).
- WACC Analysis Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters specific to ELDN.
- Customizable Forecast Inputs: Easily adjust growth projections, capital expenditures, and discount rates to fit Eledon’s business model.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Eledon Pharmaceuticals, Inc. (ELDN).
- Interactive Dashboard and Visualizations: Graphical representations highlight essential valuation metrics for streamlined analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Eledon Pharmaceuticals, Inc. (ELDN) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including the intrinsic value of Eledon Pharmaceuticals, Inc. (ELDN).
- Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by researchers, financial analysts, and industry leaders.
- Comprehensive Data: Eledon's historical and projected financials preloaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth user experience.
Who Should Use This Product?
- Investors: Accurately estimate Eledon's fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Eledon Pharmaceuticals.
- Consultants: Quickly customize the template for valuation reports tailored to Eledon Pharmaceuticals' clients.
- Entrepreneurs: Gain insights into financial modeling techniques employed by leading pharmaceutical companies.
- Educators: Use it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Eledon Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Eledon Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.